Please enable JavaScript.

Coggle requires JavaScript to display documents.

Novo Case (ABPI Code of Practice (Scope: This code of practice only…

- - - - How would you increase market share?
    - - this might pose as a problem when at international meetings - as you might be going to a meeting with the purpose of discussing changes/ promotions but certain countries there or the country you are in, you do not have market authorisation
        
        there are a few conditions: the meeting must be significantly international, relevant and proportional to the purpose of the meeting, clearly communicated that certain markets lack authorisation, providing sample promotion material for those countries which is not relevant to that country, and any material must be certified (as specified by the Code)
        
        Certification: done by a medical practionioner or pharmacist
        
        There is a requirement to provide advanced notification to the payers/policy makers (e.g. NHS) if the product being promoted will affect their ependitures.
        
        this information should be provided before the promotional material is developed and during the process of market authorisation, should also be included in the horizon database (NHS, latest news on emerging technology)
        
        Should provide non-promotional information as a way to inform the payers. This would be a description of key changes in terms of new active substance, or new substance prepared in a new way or significant addition to existing range or novel application
        
        this should only be provided to policy makers and it should state the costs or savings
  - - - PAGB is the national trade association that represents manufacturers of branded OTC mediciens and food suppls. In additin to advertising, it provides regulatory and public affairs support. There are two codes: one for the public and one for the professional.
- - - - Two key areas of interest: good health and well-being; responsible consumption and production - these are the goals that NN is confident they can make an impact with
- - - - Poor glycaemic control (i.e. blood glucose control) does lead to some serious complications. A key area is non adherence.
        
        Most common reason - fear of hypoglycaemia (confusion, trembling, sweating etc). Some might consider this more dangerous than hyperglycaemia, thus releaving the underlying route cause. In an aftermath of hypoglycaemia, 25% of pateints report reducing their insulin dose and the same amount go to their doctor
        
        another is the rigidity - 33% admit to insulin omission or non-adherence
  - - - Type 1: have to have insulin from the first moment of being diagnosed as their body no longer produces insulin, whereas for type II there is a progressive decline, so they can start wtih non-insulin based treatment (e.g. to help boost insulin secretion)
      - Three main types of insulin product: fast-acting, to have injections after each meal. Premix (biphasiic) - two injections, and long-acting